Please login to the form below

palbociclib

This page shows the latest palbociclib news and features for those working in and with pharma, biotech and healthcare.

evaluating Kisqali compared to palbociclib in patients with HR+/HER2- advanced breast cancer with aggressive tumor biology, defined as HER2-enriched.

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

ARV-471 is also being studied in a phase 1b combination study alongside Pfizer’s blockbuster CDK4/6 inhibitor Ibrance (palbociclib).
Novartis' Kisqali shows long-term improvements in breast cancer patients

Kisqali’s main rival in the HR-positive/HER2-positive breast cancer setting is Pfizer’s market leader Ibrance (palbociclib).
Pfizer, Sanofi and others set to increase US drug prices in 2021

drugs Ibrance (palbociclib) and Inlyta (axitinib).
Lilly’s Verzenio scores a win in early-stage breast cancer

The positive results for Verzenio in the early breast cancer setting will be a blow for Pfizer’s rival CDK4/6 inhibitor Ibrance (palbociclib), after the therapy failed to improve upon
Vyndaqel a bright spot as Pfizer comes under pressure

The company’s fourth-quarter results saw a 9% drop in revenues to $12.69bn, with breast cancer drug Ibrance (palbociclib) and Xeljanz (tofacitinib) for rheumatoid arthritis both growing but missing

More from news
Approximately 7 fully matching, plus 61 partially matching documents found.

20 for 2020 – Five pharma leaders to watch in 2020

to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others.
Engaging the digital healthcare professional

When NICE, the UK policymaker for health spending, rejected Pfizer’s breast cancer drug palbociclib for routine funding on the NHS in February, it tweeted the news and invited comments on ... Weeks later, following the NICE consultation period, the
Pharma deals during August 2013

Palbociclib, which is the result of an early partnership with Pfizer and now being developed by Pfizer, is in phase III trials for advanced breast cancer and certain haematologic malignancies. ... If approved, Onyx will receive an 8 per cent royalty on